Under the terms of the agreement GlaxoSmithKline (GSK) will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira’s FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to $425 million in upfront and milestone payments.
In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.